Isthmus Partners LLC lessened its holdings in shares of PAREXEL International Corporation (NASDAQ:PRXL) by 1.1% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 11,394 shares of the medical research company’s stock after selling 122 shares during the period. Isthmus Partners LLC’s holdings in PAREXEL International Corporation were worth $990,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of PRXL. Public Employees Retirement System of Ohio lifted its holdings in shares of PAREXEL International Corporation by 4.5% during the first quarter. Public Employees Retirement System of Ohio now owns 1,713 shares of the medical research company’s stock worth $108,000 after purchasing an additional 73 shares during the period. Meadow Creek Investment Management LLC lifted its holdings in shares of PAREXEL International Corporation by 7.1% during the first quarter. Meadow Creek Investment Management LLC now owns 1,980 shares of the medical research company’s stock worth $125,000 after purchasing an additional 132 shares during the period. Invictus RG acquired a new position in shares of PAREXEL International Corporation during the first quarter worth $158,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of PAREXEL International Corporation by 10.0% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,986 shares of the medical research company’s stock worth $173,000 after purchasing an additional 180 shares during the period. Finally, BlueCrest Capital Management Ltd acquired a new position in shares of PAREXEL International Corporation during the first quarter worth $202,000. Institutional investors own 87.45% of the company’s stock.

PAREXEL International Corporation (PRXL) traded up 0.051% during trading on Monday, reaching $87.995. 150,767 shares of the company traded hands. The firm has a market capitalization of $4.50 billion, a price-to-earnings ratio of 42.716 and a beta of 0.79. PAREXEL International Corporation has a 12-month low of $51.16 and a 12-month high of $88.01. The firm’s 50 day moving average price is $87.71 and its 200 day moving average price is $77.62.

PAREXEL International Corporation (NASDAQ:PRXL) last announced its quarterly earnings results on Monday, August 28th. The medical research company reported $1.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.94 by $0.08. The business had revenue of $557.20 million for the quarter, compared to analyst estimates of $537.59 million. PAREXEL International Corporation had a net margin of 4.49% and a return on equity of 28.98%. During the same quarter last year, the firm earned $0.94 EPS. Equities research analysts expect that PAREXEL International Corporation will post $3.95 earnings per share for the current year.

A number of equities analysts have recently commented on PRXL shares. Goldman Sachs Group, Inc. (The) upgraded shares of PAREXEL International Corporation from a “sell” rating to a “neutral” rating and lifted their price target for the stock from $63.00 to $77.00 in a report on Tuesday, May 23rd. Credit Suisse Group reiterated a “neutral” rating and set a $83.00 price target (up previously from $65.00) on shares of PAREXEL International Corporation in a report on Tuesday, June 6th. Zacks Investment Research upgraded shares of PAREXEL International Corporation from a “hold” rating to a “buy” rating and set a $98.00 price target on the stock in a report on Thursday, August 31st. Barclays PLC lowered shares of PAREXEL International Corporation from an “overweighr” rating to an “equal weight” rating and set a $87.00 price target on the stock. in a report on Tuesday, June 20th. Finally, Mizuho lifted their price target on shares of PAREXEL International Corporation from $66.00 to $75.00 and gave the stock a “buy” rating in a report on Tuesday, May 30th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and four have given a buy rating to the company’s stock. PAREXEL International Corporation presently has an average rating of “Hold” and an average target price of $75.92.

TRADEMARK VIOLATION NOTICE: “Isthmus Partners LLC Sells 122 Shares of PAREXEL International Corporation (PRXL)” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this report on another site, it was stolen and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.watchlistnews.com/isthmus-partners-llc-sells-122-shares-of-parexel-international-corporation-prxl/1571366.html.

PAREXEL International Corporation Company Profile

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.

Institutional Ownership by Quarter for PAREXEL International Corporation (NASDAQ:PRXL)

Receive News & Ratings for PAREXEL International Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.